Browse recruiting and upcoming clinical trials for AL amyloidosis.
Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026
About this list Hide ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.
64 trials + 5 related Sex All Female (includes ALL) Male (includes ALL) All sexes only
Age All ages Pediatric (under 18) Adult (18+)
Clear Who can join AI People aged ≥18 with newly diagnosed multiple myeloma AND concurrent AL (light‑chain) amyloidosis who have not had prior anti‑plasma cell therapy.
What is being studied AI Tests teclistamab plus daratumumab to treat newly diagnosed multiple myeloma with concurrent AL amyloidosis.
Study type Treatment (drug) · Phase 2
Who can join AI People aged 18+ with relapsed or refractory systemic light-chain (AL) amyloidosis.
What is being studied AI Tests safety, early efficacy and pharmacokinetics of BCMA-targeted autologous CAR-T infusion.
Study type Treatment (drug) · Early Phase 1
Who can join AI People with newly diagnosed amyloid light‑chain (AL) amyloidosis.
What is being studied AI Tests SCTC21C plus VCd versus VCd alone for newly diagnosed AL amyloidosis.
Study type Treatment (drug) · Phase 3
Who can join AI Adults with primary systemic (light‑chain) AL amyloidosis who test positive for t(11;14).
What is being studied AI Tests sonrotoclax + dexamethasone (± daratumumab) for hematologic and organ response in t(11;14) AL amyloidosis
Study type Treatment (drug) · Phase 2
Who can join AI Adults (18–80) with systemic light chain (AL) amyloidosis with measurable disease who have relapsed or progressed after prior systemic treatment.
What is being studied AI Evaluates safety, pharmacokinetics, immunogenicity, and hematologic response to TQB2934 injection.
Study type Treatment (drug) · Phase 1/2
Who can join AI Adults (18+) with relapsed or refractory AL (light-chain) amyloidosis.
What is being studied AI Tests safety, tolerability, and early activity of GC012F (CD19/BCMA) CAR‑T in relapsed/refractory AL amyloidosis.
Study type Treatment (drug) · Phase 1
Who can join AI Adults (≥18 years) with newly diagnosed primary AL (amyloid light‑chain) amyloidosis.
What is being studied AI Evaluates belantamab mafodotin with cyclophosphamide, bortezomib and dexamethasone for AL amyloidosis.
Study type Treatment (drug) · Phase 2
Countries Australia, United States
Who can join AI People aged 18–70 with newly diagnosed systemic light‑chain (AL) amyloidosis who achieved hematologic CR after 2–4 cycles of Dara‑CyBorD and meet ASCT criteria.
What is being studied AI Tests MRD status and whether ASCT after Dara-CyBorD affects outcomes in AL amyloidosis.
Study type Treatment (drug)
Who can join AI Adults (age ≥18) with newly diagnosed systemic light‑chain (AL) amyloidosis who have measurable disease.
What is being studied AI Tests low-dose BCMA/CD3 bispecific antibody (CM336) given subcutaneously for newly diagnosed AL amyloidosis.
Study type Treatment (drug) · Phase 2
Who can join AI Adults (18–100) with newly diagnosed, previously untreated systemic AL (light‑chain) amyloidosis.
What is being studied AI Tests teclistamab plus daratumumab as treatment for newly diagnosed AL amyloidosis.
Study type Treatment (drug) · Phase 2
Who can join AI Adults 19–75 with relapsed or refractory plasma cell neoplasms (multiple myeloma, plasma cell leukemia, or AL amyloidosis) after ≥3 prior therapies.
What is being studied AI Tests safety, dosing, and behavior of Meta10-BCMA CAR-T cells in relapsed/refractory plasma cell neoplasms.
Study type Treatment (drug) · Early Phase 1
Who can join AI Adults (18+) with relapsed or refractory AL (light-chain) amyloidosis.
What is being studied AI Tests safety, tolerability and activity of AZD0120 CAR T cell therapy in AL amyloidosis.
Study type Treatment (drug) · Phase 1/2
Countries Canada, United Kingdom, United States
Who can join AI People aged 18 years or older with newly diagnosed Mayo stage IIIB AL (light‑chain) amyloidosis.
What is being studied AI Tests teclistamab given by subcutaneous injection for safety and light-chain response in AL amyloidosis.
Study type Treatment (drug) · Phase 2
Who can join AI Adults (≥18 years) with relapsed or refractory primary light‑chain (AL) amyloidosis with measurable hematologic disease and at least one organ involved.
What is being studied AI Tests safety and hematologic complete response rate of subcutaneous CM336 at two dose levels.
Study type Treatment (drug) · Phase 2
Who can join AI Adults (≥18 years) with recurrent or refractory light chain amyloidosis who have received second-line or later treatment.
What is being studied AI Tests safety and preliminary effectiveness of a single fixed dose BCMA autologous CAR‑T cell infusion.
Study type Treatment (drug)
Who can join AI People aged 18 or older with relapsed or refractory multiple myeloma or light‑chain (AL) amyloidosis with measurable disease.
What is being studied AI Tests safety and efficacy of a single infusion of HBI0101 (BCMA) CAR‑T cells.
Study type Treatment (drug) · Phase 2
Who can join AI Adults (≥18) with biopsy‑confirmed AL (light‑chain) amyloidosis who were previously treated, including daratumumab and bortezomib.
What is being studied AI Tests subcutaneous teclistamab as a treatment for previously treated AL amyloidosis.
Study type Treatment (drug) · Phase 2
Who can join AI People with multiple myeloma, high-risk smoldering multiple myeloma, or immunoglobulin light-chain (AL) amyloidosis.
What is being studied AI Tests safety, tolerability, and doses of JNJ-79635322 combined with daratumumab, lenalidomide or pomalidomide.
Study type Treatment (drug) · Phase 1
Countries Australia, Israel, Netherlands +2
Who can join AI People with systemic AL amyloidosis who have not achieved a complete hematological response after prior daratumumab and bortezomib.
What is being studied AI Tests teclistamab as a drug treatment to produce complete hematological response in AL amyloidosis.
Study type Treatment (drug)
Who can join AI Adults (≥18) with relapsed or refractory AL (light‑chain) amyloidosis with evidence of progressing light‑chain disease (dFLC >20 mg/L).
What is being studied AI Tests subcutaneous elranatamab for safety, tolerability and hematologic response in relapsed or refractory AL amyloidosis.
Study type Treatment (drug) · Phase 1/2
Who can join AI Adults with biopsy-confirmed renal AL (light-chain) amyloidosis and urine protein >1.0 g/day.
What is being studied AI Tests whether dapagliflozin is safe and whether it reduces urine protein in renal AL amyloidosis.
Study type Treatment (drug) · Phase 2
Who can join AI People aged 18–75 with newly diagnosed systemic light chain (AL) amyloidosis.
What is being studied AI Tests daratumumab-based regimens, with or without ASCT or pomalidomide, in newly diagnosed AL amyloidosis.
Study type Treatment (drug)
Who can join AI Adults (18–90 years) with newly diagnosed or previously treated systemic AL (light‑chain) amyloidosis.
What is being studied AI Tests bortezomib + pomalidomide + dexamethasone for systemic AL amyloidosis.
Study type Treatment (drug) · Phase 2
Who can join AI Adults with relapsed or refractory systemic light‑chain (AL) amyloidosis who need further treatment.
What is being studied AI Tests linvoseltamab's safety, dosing, and activity in relapsed/refractory AL amyloidosis.
Study type Treatment (drug) · Phase 1/2
Countries Greece, South Korea, Spain +3
Who can join AI People with systemic AL (light‑chain) amyloidosis with t(11;14).
What is being studied AI Tests first-line treatments for systemic AL amyloidosis with t(11;14).
Study type Treatment (drug)
Who can join AI Adults with immunoglobulin light chain (AL) amyloidosis.
What is being studied AI Tests safety and disease-activity changes with IV Etentamig (ABBV-383) in AL amyloidosis.
Study type Treatment (drug) · Phase 1/2
Countries Australia, France, Greece +3
Who can join AI People aged 18+ with newly diagnosed, biopsy-proven systemic AL (light-chain) amyloidosis.
What is being studied AI Compares Dara‑VCD followed by autologous stem cell transplant with Dara‑VCD alone.
Study type Treatment (drug) · Phase 3
Who can join AI Adults (≥18) with confirmed AL (light‑chain) amyloidosis who meet the study's treatment and testing requirements.
What is being studied AI Compares shorter versus longer daratumumab maintenance after daratumumab-based induction.
Study type Treatment (drug) · Phase 2
Who can join AI Adults (18+) with relapsed or refractory multiple myeloma or previously treated AL (amyloid light‑chain) amyloidosis.
What is being studied AI Tests safety, tolerability, and dose(s) of JNJ-79635322 in these patients.
Study type Treatment (drug) · Phase 1
Countries Belgium, France, Japan +4
Who can join AI Adults (18+) with relapsed or refractory primary systemic AL (light-chain) amyloidosis.
What is being studied AI Tests safety, side effects, and dose of belantamab mafodotin in relapsed/refractory AL amyloidosis.
Study type Treatment (drug) · Phase 1/2
Who can join AI People with newly diagnosed Amyloid Light Chain (AL) amyloidosis.
What is being studied AI Compares safety, hematologic response, and organ outcomes of etentamig versus Dara-CyBorD.
Study type Treatment (drug) · Phase 3
Who can join AI People with relapsed or refractory primary light chain (AL) amyloidosis.
What is being studied AI Tests safety and activity of FKC289 (anti-BCMA/CD19 CAR-T) in relapsed/refractory AL amyloidosis.
Study type Treatment (drug) · Phase 1/2
Who can join AI People with newly diagnosed systemic light-chain (AL) amyloidosis.
What is being studied AI Tests QLS4131 trispecific antibody as a frontline treatment for AL amyloidosis.
Study type Treatment (drug) · Phase 2
Who can join AI Adults (18+) with newly diagnosed light‑chain (AL) amyloidosis involving one or more organs.
What is being studied AI Compares CAR-T therapy NXC-201 with daratumumab plus CyBorD in newly diagnosed AL amyloidosis.
Study type Treatment (drug) · Phase 3
Who can join AI Adults (18–70) with newly diagnosed systemic primary (light‑chain, AL) amyloidosis who have not received systemic anti‑tumor therapy.
What is being studied AI Tests sonrotoclax+dexamethasone for t(11;14) cases and a BCMA/CD3 bispecific antibody for others.
Study type Treatment (drug) · Phase 1/2
Who can join AI People with biopsy-confirmed AL amyloidosis who have measurable amyloidoma tissue on imaging.
What is being studied AI Tests anselamimab binding to amyloid in vivo and its effects on lesion size.
Study type Treatment (drug) · Early Phase 1
Who can join AI Adults (age ≥18) with newly diagnosed, treatment‑naive immunoglobulin light‑chain (AL) amyloidosis.
What is being studied AI Compares two 6‑month dosing schedules of elranatamab (BCMA bispecific) in newly diagnosed AL amyloidosis.
Study type Treatment (drug) · Phase 2
Who can join AI Adults (≥18 years) with newly diagnosed AL (light-chain) amyloidosis at Mayo Stage IIIb.
What is being studied AI Tests whether a single infusion of Eque-cel CAR-T induces hematologic remission in Mayo Stage IIIb AL amyloidosis.
Study type Treatment (drug) · Phase 2
Who can join AI People with systemic amyloidosis (including AL and ATTR) and healthy volunteers.
What is being studied AI Tests 99mTc-p5+14 SPECT/CT and planar imaging to map amyloid biodistribution and dosimetry.
Who can join AI Adults (18–99) with systemic light‑chain (AL) amyloidosis (with or without heart involvement), and control groups with multiple myeloma or heart failure without amyloidosis.
What is being studied AI PET and cardiac MRI plus blood and microbiome tests to measure cardiac amyloid, metabolism, and microvascular function
Who can join AI People with monoclonal gammopathy (including MGUS and multiple myeloma) or with AL/systemic amyloidosis.
What is being studied AI Whether 18F‑florbetaben PET/MR detects systemic amyloid deposits noninvasively in monoclonal gammopathy.
Who can join AI People with known or suspected cardiac amyloidosis.
What is being studied AI Tests [18F]Fluselenamyl PET imaging's ability to detect heart amyloid deposits.
Who can join AI Adults (18+) with the listed cancers or blood disorders who have had at least two injections of one of the study biotherapies.
What is being studied AI Skin prick and intradermal tests to find non-irritant concentrations for biotherapy allergy evaluation.
Who can join AI People with Multiple Myeloma or AL (systemic light‑chain) amyloidosis.
What is being studied AI Daily SMS symptom reports and questionnaires to track symptoms, alerts, and quality-of-life over three months.
Who can join AI Adults (18–99 years) with biopsy-proven systemic AL amyloidosis, POEMS syndrome, or multiple myeloma.
What is being studied AI Collects and analyzes IGLV1-44 light-chain sequences and biophysical properties to find disease-associated fingerprints.
Who can join AI People with AL amyloidosis, MGUS, multiple myeloma, or other monoclonal gammopathies.
What is being studied AI Collects light-chain sequences and clinical data to study N-glycosylation in monoclonal gammopathies
Who can join AI Adults (18+) with suspected or confirmed amyloidosis (any subtype), including AL and cardiac amyloidosis.
What is being studied AI Collects and stores blood, urine, tissue and clinical data from people with amyloidosis.
Who can join AI People aged ≥18 with multiple myeloma, primary plasma cell leukemia, or AL amyloidosis planned to start specified immunotherapies outside a clinical trial.
What is being studied AI Collects real-world outcomes and harms of certain immunotherapies for plasma-cell diseases.
Who can join AI Adults aged 18–99 with newly diagnosed systemic AL amyloidosis who are treatment‑naïve and can give informed consent.
What is being studied AI Collects clinical data and biosamples to study molecular features, disease course, and minimal residual disease.
Countries Germany, Italy, Netherlands +3
Who can join AI Adults 18–80 years with Immunoglobulin Light Amyloidosis Cardiomyopathy (AL-CM).
What is being studied AI Collects treatment information and long-term outcomes, including major cardiovascular events over 10 years.
Who can join AI Older people with a confirmed or presumed cancer diagnosis, including leukemia, lymphoma, multiple myeloma, and other solid tumors.
What is being studied AI Collects geriatric assessments and medical-record information for older patients with cancer.
Who can join AI People being evaluated for a hematologic cancer or related blood or lymphoid disorder (leukemia, lymphoma, multiple myeloma, myelodysplastic and myeloproliferative disorders, and related neoplasms) at the University of North Carolina Hospitals — in the hematology/oncology clinics, the stem cell transplant clinic, or as an inpatient.
What is being studied AI Collects and stores blood, tissue, and body-fluid samples for future laboratory research.
Who can join AI People diagnosed with or suspected of having amyloidosis, and people with multiple myeloma.
What is being studied AI Collects and stores blood, urine, tissue, and clinical data for laboratory study.
Who can join AI Adults (≥18 years) diagnosed with systemic amyloidosis, including AL, ATTR, or amyloid cardiomyopathy.
What is being studied AI Collects clinical, imaging, laboratory and treatment data on people with systemic amyloidosis.
Who can join AI Adults with suspected or confirmed cardiac or systemic amyloidosis, and healthy adult volunteers.
What is being studied AI Tests [18F]FT8 PET/CT for safety and organ uptake in amyloidosis patients and healthy controls.
Who can join AI People aged 18+ diagnosed with cardiac AL or ATTR amyloidosis.
What is being studied AI Collects clinical and imaging data to track outcomes and progression in cardiac amyloidosis patients.
Countries Belgium, Italy, Japan +2
Who can join AI Adults (18+) with suspected or confirmed systemic or cardiac amyloidosis.
What is being studied AI Collects clinical, imaging, lab and outcome data from people with systemic and cardiac amyloidosis.
Who can join AI Adults 18–99 with systemic AL amyloidosis treated with daratumumab + bortezomib + dexamethasone and dFLC ≥50 mg/L.
What is being studied AI If a rapid drop in dFLC predicts complete hematologic response to daratumumab-based therapy.
Who can join AI People aged 18–99 with AL amyloidosis, smoldering multiple myeloma (SMM), or MGUS with abnormal free light‑chain ratio (aFLCR).
What is being studied AI Tests biomarker-based screening and clonal light-chain analyses to detect and characterize AL amyloidosis.
Who can join AI Children and people with one of the many rare kidney diseases listed in this registry.
What is being studied AI Collects clinical data, patient-reported outcomes, and samples to support research.
Who can join AI Adults (18–99) with diagnosed systemic AL amyloidosis who are treatment‑naïve and followed at a participating center.
What is being studied AI Collects real-world clinical data at diagnosis and during follow-up from people with AL amyloidosis.
Who can join AI Adults (18+) diagnosed with plasma cell disorders such as MGUS, AL amyloidosis, or multiple myeloma.
What is being studied AI Collects patient data and blood/bone marrow samples and tracks disease course for research.
Who can join AI People with light‑chain (AL) cardiac amyloidosis.
What is being studied AI Tests whether a multimodal radiomics model predicts 12-month mortality and tracks disease changes.
Who can join AI People aged 18–75 with newly diagnosed, biopsy‑proven AL amyloidosis or plasma cell dyscrasia who are candidates for autologous stem cell transplant.
What is being studied AI Collects and analyzes outcomes after autologous stem cell transplantation, including induction and maintenance.
Trials that may include AL amyloidosis (5) ClinicalTrials.gov returned these when we searched for this condition, but we could not confirm from the registry records that they are intended for people with it. Check each trial’s eligibility criteria, and ask the study team if you are unsure.
Who can join AI People aged 18+ with primary cutaneous amyloidosis (including macular or lichen amyloidosis).
What is being studied AI Compares tofacitinib plus acitretin versus acitretin alone for symptoms and safety.
Study type Treatment (drug) · Phase 4
Who can join AI People with newly diagnosed monoclonal immunoglobulin deposition disease (MIDD).
What is being studied AI Tests a combination drug regimen (daratumumab, bortezomib, cyclophosphamide, dexamethasone) in newly diagnosed MIDD.
Study type Treatment (drug) · Phase 2
Who can join AI People with primary cutaneous amyloidosis.
What is being studied AI Tests safety and efficacy of Stapokibart versus placebo in primary cutaneous amyloidosis.
Study type Treatment (drug)
Who can join AI People 40 years or older with smoldering multiple myeloma or a monoclonal gammopathy who meet specified free light-chain test results.
What is being studied AI Screening for undiagnosed light-chain (AL) amyloidosis and developing a prediction algorithm.
Who can join AI Adults (18–99) with suspected or confirmed ATTR amyloidosis (people with AL [light‑chain] amyloidosis are excluded).
What is being studied AI Collects clinical data to define natural history and validate prognostic and response models for ATTR amyloidosis